Clinical trials: FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma
Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma
PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer
This clinical trial studies positron emission tomography (PET)/computed tomography (CT) and lymph node mapping in finding lymph node metastasis in patients with endometrial cancer that is at high risk of spreading.
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma, Grade 3 Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT01737619
- Testing
- Computed Tomography, Indocyanine Green Solution, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 101 people
- Sponsor
- M.D. Anderson Cancer Center
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
This randomized surgical window trial evaluates the effect of adding entinostat to medroxyprogesterone acetate before surgery works on progesterone receptors on endometrioid endometrial tumors.
- Conditions
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT03018249
- Testing
- Entinostat, Hysterectomy, Laboratory Biomarker Analysis
- Where
- 234 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Cytoreductive Surgery, Grade 3 Endometrial Endometrioid Adenocarcinoma
PET/MRI in Endometrial Cancer
This study is investigating if positron emission tomography (PET)/Magnetic resonance imaging (MRI) is more effective than the currently used imaging modalities (computed tomography [CT], or PET/CT) for high-risk endometrial…
- Conditions
- Cytoreductive Surgery, Grade 3 Endometrial Endometrioid Adenocarcinoma, High Grade Serous Carcinoma, Endometrial Undifferentiated Carcinoma
- Trial name
- NCT05390021
- Testing
- PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent
- Sponsor
- Massachusetts General Hospital